logo-loader
viewTrueCar

TrueCar shares sputter after CEO Chip Perry retires

The company named executive vice president Michael Darrow interim CEO

Vehicle
TrueCar is a digital automotive marketplace focused on price transparency

TrueCar Inc (NASDAQ:TRUE) stock skidded after CEO Chip Perry announced his retirement Monday morning.

The online car marketplace named Michael Darrow interim CEO. Darrow is currently executive vice president of partner and OEM development.

Investors pumped the brakes, sending the share price down more than 13% to $5.66 at midday.

READ: TrueCar looks to 2019 for revenue growth on back of 4Q earnings

"On behalf of the Board of Directors, I want to sincerely thank Chip for the leadership he has brought to TrueCar over the last few years, rebuilding our dealer customer base, reinventing our technology platform, and setting the stage for TrueCar's growth as a best-in-class online automotive marketplace,” Chairman Chris Claus said. “We are grateful to Chip and wish him all the best in his retirement. We appreciate his deep commitment to TrueCar, and we thank him for his service."

Perry plans to continue with the company in an advisory capacity.

TrueCar is a digital automotive marketplace focused on price transparency. it operates within a nationwide network of 16,000 certifide dealers. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: TrueCar

Price: 3.74 USD

NASDAQ:TRUE
Market: NASDAQ
Market Cap: $398.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex sees newly licensed diabetes gene therapy as an...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes. Varner says the newly licensed diabetes gene...

2 days ago

2 min read